Cargando…
Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age
PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive status...
Autores principales: | Chen, Yen-Chih, Chen, San-Ni, Yang, Benjamin Chi-Lan, Lee, Kun-Hsien, Chuang, Chih-Chun, Cheng, Chieh-Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/ https://www.ncbi.nlm.nih.gov/pubmed/29713524 http://dx.doi.org/10.1155/2018/4565216 |
Ejemplares similares
-
Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity
por: Pawar, Neelam, et al.
Publicado: (2023) -
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016) -
Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022) -
Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity
por: Huang, Ching-Yen, et al.
Publicado: (2022) -
Intravitreal Injection of Bevacizumab for Retinopathy of Prematurity in an Infant with Peters Anomaly
por: Minami, Tsuyoshi, et al.
Publicado: (2014)